

Low-Dose Naltrexone References

- Beck, John (The Medicine Shoppe, Georgetown, SC). Conversation with: Lauren Linder Wier (Affiliation, City, State). 2022 Apr 27.
- Bolton MJ, Chapman BP, Van Marwijk H. Low-dose naltrexone as a treatment for chronic fatigue syndrome. *BMJ Case Rep*. 2020 Jan 6;13(1):e232502. doi: 10.1136/bcr-2019-232502.
- Bolton M, Hodgkinson A, Boda S, et al. Serious adverse events reported in placebo randomised controlled trials of oral naltrexone: a systematic review and meta-analysis. *BMC Med*. 2019 Jan 15;17(1):10. doi: 10.1186/s12916-018-1242-0.
- Bostick KM, McCarter AG, Nykamp D. The use of low-dose naltrexone for chronic pain. *Sr Care Pharm*. 2019 Jan 1;34(1):43-46. doi: 10.4140/TCP.n.2019.43.
- Bronfenbrener R. Inexpensive compounding of low-dose naltrexone (LDN) with orange juice. *J Am Acad Dermatol*. 2021 Sep;85(3):e139. doi: 10.1016/j.jaad.2019.03.067.
- Bruun KD, Amris K, Vaegter HB, et al. Low-dose naltrexone for the treatment of fibromyalgia: protocol for a double-blind, randomized, placebo-controlled trial. *Trials*. 2021 Nov 15;22(1):804. doi: 10.1186/s13063-021-05776-7.
- Bruun-Plesner K, Blichfeldt-Eckhardt MR, Vaegter HB, Lauridsen JT, Amris K, Toft P. Low-dose naltrexone for the treatment of fibromyalgia: investigation of dose-response relationships. *Pain Med*. 2020 Oct 1;21(10):2253-2261. doi: 10.1093/pm/pnaa001.
- Chindalore VL, Craven RA, Yu KP, Butera PG, Burns LH, Friedmann N. Adding ultralow-dose naltrexone to oxycodone enhances and prolongs analgesia: a randomized, controlled trial of Oxytrex. *J Pain*. 2005 Jun;6(6):392-9. doi: 10.1016/j.jpain.2005.01.356.
- Chopra P, Cooper MS. Treatment of Complex Regional Pain Syndrome (CRPS) using low dose naltrexone (LDN). *J Neuroimmune Pharmacol*. 2013 Jun;8(3):470-6. doi: 10.1007/s11481-013-9451-y.
- Clear up confusion about low-dose naltrexone. *Pharmacist's Letter* [Internet]. Stockton, CA: Therapeutic Research Center; [updated 2020 Apr]. Available from: <https://pharmacist.therapeuticresearch.com/en/Content/Articles/PL/2020/Apr/Clear-Up-Confusion-About-Low-Dose-Naltrexone>
- Colomer-Carbonell A, Sanabria-Mazo JP, Hernández-Negrín H, et al Study protocol for a randomised, double-blinded, placebo-controlled phase III trial examining the add-on efficacy, cost-utility and neurobiological effects of low-dose naltrexone (LDN) in patients with fibromyalgia (INNOVA study). *BMJ Open*. 2022 Jan 6;12(1):e055351. doi: 10.1136/bmjopen-2021-055351.
- Cree BA, Kornyeveva E, Goodin DS. Pilot trial of low-dose naltrexone and quality of life in multiple sclerosis. *Ann Neurol*. 2010 Aug;68(2):145-50. doi: 10.1002/ana.22006.
- Dieckmann G, Ozmen MC, Cox SM, Engert RC, Hamrah P. Low-dose naltrexone is effective and well-tolerated for modulating symptoms in patients with neuropathic corneal pain. *Ocul Surf*. 2021 Apr;20:33-38. doi: 10.1016/j.jtos.2020.12.003.
- Ghai B, Bansal D, Hota D, Shah CS. Off-label, low-dose naltrexone for refractory chronic low back pain. *Pain Med*. 2014 May;15(5):883-4. doi: 10.1111/pme.12345.
- Hatfield E, Phillips K, Swidan S, Ashman L. Use of low-dose naltrexone in the management of chronic pain conditions: A systematic review. *J Am Dent Assoc*. 2020 Dec;151(12):891-902.e1. doi: 10.1016/j.adaj.2020.08.019.
- Hawthorne Compounding Pharmacy (Wendy). Columbia, SC. Conversation with: Lauren Linder Wier (Affiliation, City, State). 2022 Apr 27.
- Hota D, Srinivasan A, Dutta P, Bhansali A, Chakrabarti A. Off-Label, Low-Dose Naltrexone for Refractory Painful Diabetic Neuropathy. *Pain Med*. 2016 Apr;17(4):790-1. doi: 10.1093/pm/pnv009. Epub 2015 Dec 7.
- Jackson D, Singh S, Zhang-James Y, Faraone S, Johnson B. The effects of low dose naltrexone on opioid induced hyperalgesia and fibromyalgia. *Front Psychiatry*. 2021 Feb 16;12:593842. doi: 10.3389/fpsy.2021.593842.
- Leonard JB, Nair V, Diaz CJ, Penoyar JB, Goode PA. Potential drug interaction with opioid agonist in the setting of chronic low-dose opioid antagonist use. *Am J Emerg Med*. 2017 Aug;35(8):1209.e3-1209.e4. doi: 10.1016/j.ajem.2017.04.012.
- Low-dose naltrexone. *Pharmacist's Letter* [Internet]. Stockton, CA: Therapeutic Research Center; [updated 2020 Apr]. Available from: <https://pharmacist.therapeuticresearch.com/Content/Segments/PRL/2020/Apr/Low-Dose-Naltrexone-S2004002>
- Kim PS, Fishman MA. Low-dose naltrexone for chronic pain: update and systemic review. *Curr Pain Headache Rep*. 2020 Aug 26;24(10):64. doi: 10.1007/s11916-020-00898-0.
- Mischoulon D, Hylek L, Yeung AS, et al. Randomized, proof-of-concept trial of low dose naltrexone for patients with breakthrough symptoms of major depressive disorder on antidepressants. *J Affect Disord*. 2017 Jan 15;208:6-14. doi: 10.1016/j.jad.2016.08.029. Erratum in: *J Affect Disord*. 2017 Oct 27;227:198.

Low-Dose Naltrexone References

- Neuman DL, Chadwick AL. Utilization of low-dose naltrexone for burning mouth syndrome: a case report. *A A Pract*. 2021 May 17;15(5):e01475. doi: 10.1213/XAA.0000000000001475.
- Oaks Z, Stage A, Middleton B, Faraone S, Johnson B. Clinical utility of the cold pressor test: evaluation of pain patients, treatment of opioid-induced hyperalgesia and fibromyalgia with low dose naltrexone. *Discov Med*. 2018 Nov;26(144):197-206.
- Patten DK, Schultz BG, Berlau DJ. The safety and efficacy of low-dose naltrexone in the management of chronic pain and inflammation in multiple sclerosis, fibromyalgia, Crohn's disease, and other chronic pain disorders. *Pharmacotherapy*. 2018 Mar;38(3):382-389. doi: 10.1002/phar.2086.
- Parkitny L, Younger J. Reduced pro-inflammatory cytokines after eight weeks of low-dose naltrexone for fibromyalgia. *Biomedicines*. 2017 Apr 18;5(2):16. doi: 10.3390/biomedicines5020016.
- Peyravian N, Dikici E, Deo S, Toborek M, Daunert S. Opioid antagonists as potential therapeutics for ischemic stroke. *Prog Neurobiol*. 2019 Nov;182:101679. doi: 10.1016/j.pneurobio.2019.101679.
- Raknes G, Småbrekke L. Low dose naltrexone: effects on medication in rheumatoid and seropositive arthritis. A nationwide register-based controlled quasi-experimental before-after study. *PLoS One*. 2019 Feb 14;14(2):e0212460. doi: 10.1371/journal.pone.0212460.
- Shaheed G, Manjooran AP, Reddy AJ, Nawathey N, Habib S, Brahmabhatt H. Low-dose naltrexone co-treatment in the prevention of opioid-induced hyperalgesia. *Cureus*. 2021 Sep 2;13(9):e17667. doi: 10.7759/cureus.17667.
- Sharafaddinzadeh N, Moghtaderi A, Kashipazha D, Majdinasab N, Shalbafan B. The effect of low-dose naltrexone on quality of life of patients with multiple sclerosis: a randomized placebo-controlled trial. *Mult Scler*. 2010 Aug;16(8):964-9. doi: 10.1177/1352458510366857.
- Shaw's Pharmacy. Greenville, SC. Conversation with: Lauren Linder Wier (Affiliation, City, State). 2022 Apr 27.
- Smith JP, Bingaman SI, Ruggiero F, et al. Therapy with the opioid antagonist naltrexone promotes mucosal healing in active Crohn's disease: a randomized placebo-controlled trial. *Dig Dis Sci*. 2011 Jul;56(7):2088-97. doi: 10.1007/s10620-011-1653-7.
- Smith JP, Field D, Bingaman SI, Evans R, Mauger DT. Safety and tolerability of low-dose naltrexone therapy in children with moderate to severe Crohn's disease: a pilot study. *J Clin Gastroenterol*. 2013 Apr;47(4):339-45. doi: 10.1097/MCG.0b013e3182702f2b.
- Srinivasan A, Dutta P, Bansal D, Chakrabarti A, Bhansali AK, Hota D. Efficacy and safety of low-dose naltrexone in painful diabetic neuropathy: A randomized, double-blind, active-control, crossover clinical trial. *J Diabetes*. 2021 Oct;13(10):770-778. doi: 10.1111/1753-0407.13202.
- Soin A, Soin Y, Dann T, et al. Low-dose naltrexone use for patients with Chronic Regional Pain Syndrome: a systematic literature review. *Pain Physician*. 2021 Jul;24(4):E393-E406.
- Tidewater Pharmacy. Charleston, SC. Conversation with: Lauren Linder Wier (Affiliation, City, State). 2022 Apr 27.
- Toljan K, Vrooman B. Low-dose naltrexone (LDN)-review of therapeutic utilization. *Med Sci (Basel)*. 2018 Sep 21;6(4):82. doi: 10.3390/medsci6040082.
- Trofimovitch D, Baumrucker SJ. Pharmacology update: low-dose naltrexone as a possible nonopioid modality for some chronic, nonmalignant pain syndromes. *Am J Hosp Palliat Care*. 2019 Oct;36(10):907-912. doi: 10.1177/1049909119838974.
- Webster LR, Butera PG, Moran LV, Wu N, Burns LH, Friedmann N. Oxytrex minimizes physical dependence while providing effective analgesia: a randomized controlled trial in low back pain. *J Pain*. 2006 Dec;7(12):937-46. doi: 10.1016/j.jpain.2006.05.005.
- Younger J, Mackey S. Fibromyalgia symptoms are reduced by low-dose naltrexone: a pilot study. *Pain Med*. 2009 May-Jun;10(4):663-72. doi: 10.1111/j.1526-4637.2009.00613.x.
- Younger J, Parkitny L, McLain D. The use of low-dose naltrexone (LDN) as a novel anti-inflammatory treatment for chronic pain. *Clin Rheumatol*. 2014 Apr;33(4):451-9. doi: 10.1007/s10067-014-2517-2.
- Younger J, Noor N, McCue R, Mackey S. Low-dose naltrexone for the treatment of fibromyalgia: findings of a small, randomized, double-blind, placebo-controlled, counterbalanced, crossover trial assessing daily pain levels. *Arthritis Rheum*. 2013 Feb;65(2):529-38. doi: 10.1002/art.37734.